Esperovax and ginkgo bioworks announce partnership to develop circular rna-based therapeutics

Initial focus of partnership will aim to develop cancer therapeutics plymouth, mich. and boston , jan. 5, 2023 /prnewswire/ -- esperovax, an innovative developer of oral mrna biologics, and ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular rnas (circrnas) for a variety of therapeutic applications.
DNA Ratings Summary
DNA Quant Ranking